Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Carmat to resume implants of Aeson artificial heart in October

Published 31/01/2022, 17:26
Updated 31/01/2022, 17:30
© Reuters.

© Reuters.

(Reuters) -French artificial heart maker Carmat said on Monday it would resume implants of its Aeson artificial heart in October, after it suspended them in December because quality issues affected some of the devices.

"A rigorous investigation concluded that quality defects on two distinct components of the prosthesis were the root cause of these issues," the group said in a statement.

Following corrective action to prevent these defects and taking account of production lead-times, new prostheses should be available by October 2022, Carmat said, specifying it had sufficient resources to finance its activities through to July.

In December, Carmat said it had completed an internal investigation into the quality issues that led to the suspension of its device implants earlier in the month.

Since the news, Carmat shares have lost almost 30% in value and closed at 16.74 euros on Monday, compared to its pre-suspension price of 24.20 euros.

Given recurring shortages of donors for heart transplants, Aeson is intended to treat patients with end-stage biventricular heart failure, a potentially fatal condition when the heart is no longer able to pump blood adequately around the body.

It launched commercially as a "bridge to transplant" last year after receiving the CE marking, which indicates a product is made to European Economic Area standards. In the United States, it is not available commercially, but is being used within clinical trials.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.